Abstracts tagged "Infection"

Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
Abstract Number: 282 • 2017 ACR/ARHP Annual Meeting
The Value of Imaging As an Early Noninvasive Test for Prosthetic Joint Septic Arthritis
Kevin Byrne¹, Mary Louise Fowler², Sarah Lieber³, Robert Shmerling⁴ and Ziv Paz³, ¹Boston University School of Medicine, Boston, MA, ²2Boston University School of Medicine, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Medical imaging is commonly obtained in evaluating patients with suspected prosthetic joint septic arthritis (PJSA); it may be helpful to detect other pathology in…
Abstract Number: 2333 • 2017 ACR/ARHP Annual Meeting
Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Joost Swart¹, Gabriella Giancane^1,2, Elio Castagnola¹, Andreas Groll¹, Gerd Horneff¹, Hans-Iko Huppertz¹, Daniel J Lovell³, Tom Wolfs¹, Michaël Hofer¹, Ekaterina Alexeeva¹, Violeta Vladislava Panaviene¹, Susan Nielsen¹, Jordi Anton¹, Florence Uettwiller¹, Valda Stanevicha¹, Maria Trachana¹, Fabrizio De Benedetti¹, Constantin Ailioaie¹, Elena Tsitsami¹, Sylvia S.M. Kamphuis¹, Troels Herlin¹, Pavla Dolezalová¹, Gordana Susic¹, Berit Flato¹, Flavio Sztajnbok¹, Elena Fueri⁴, Francesca Bovis⁵, Francesca Bagnasco¹, Angela Pistorio¹, Alberto Martini⁶, Nico Wulffraat⁷ and Nicolino Ruperto⁶, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ²Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁴Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ⁵Università degli Studi di Genova, Genoa, Italy, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Pharmachild is a pharmacovigilance registry on children with JIA treated mainly with biologics ± methotrexate (MTX). Little evidence exists in literature about the role…
Abstract Number: 386 • 2017 ACR/ARHP Annual Meeting
Analysis of the Effectiveness of Immunization with Pneumococcal Polysaccharide Vaccine in Children with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya¹, Rina Denisova¹, Olga Lomakina¹, Ksenia Isaeva¹, Margarita Soloshenko¹, Anna Karaseva¹, Nikolay Mayansky³, Irina Zubkova³, Darija Novikova⁴, Anna Gayvoronskaya⁴, Natalia Tkachenko⁴, Marika Ivardava⁴, Firuza Shakhtakhtinskaya⁴ and Marina Fedoseenko⁴, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Clinical laboratory, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ⁴Department of Vaccine Prevention, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most frequent and most disabling rheumatic diseases in childhood. Children suffering from JIA receiving immunosuppressive and…
Abstract Number: 2410 • 2017 ACR/ARHP Annual Meeting
Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study
Bella Y. Mehta¹, Sofia Pedro², Gulsen Ozen³ and Kaleb Michaud⁴, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Serious infections (SI) in patients with rheumatoid arthritis (RA) are a perpetual concern. We compared the risk by first and recurrent SIs in patients…
Abstract Number: 496 • 2017 ACR/ARHP Annual Meeting
Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections
Dimitrios A. Pappas^1,2, George W. Reed^1,3, Steve Zlotnick⁴, Jennie Best⁴, Robert Magner³, Gioia Persuitte¹ and Jeffrey D Greenberg^1,5, ¹Corrona, LLC, Southborough, MA, ²Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ³University of Massachusetts Medical School, Worcester, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Extended observations in clinical trials have not demonstrated an increased risk of serious infection events (SIE) in patients with rheumatoid arthritis (RA) treated with…
Abstract Number: 2428 • 2017 ACR/ARHP Annual Meeting
Epstein-Barr Virus Infection and Epstein-Barr Virus　Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis
Shotaro Masuoka¹, Natsuko Kusunoki¹, Shinichi Kawai² and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Department of Inflammation and Pain Control Research, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Epstein-Barr virus (EBV) infection causes various malignant tumors such as B cell lymphoma and epithelial cell cancer. Previous reports showed several variants in carboxyl-terminal…
Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Anne Lemaire¹, Roderau Outh¹, Alexandre Mania¹, Geoffroy Marceau², Pauline Berland³, Marc Andre⁴ and Olivier Aumaître⁵, ¹Internal Medicine CHU G Montpied, Internal Medicine, CLERMONT-FERRAND, France, ²Biology, Medical Biochemistry, CLERMONT-FERRAND, France, ³Epidemiology, Epidemiology, CLERMONT-FERRAND, France, ⁴Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…
Abstract Number: 403 • 2016 ACR/ARHP Annual Meeting
High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Juliana Brunelli¹, Ana Renata Schmidt¹, Adriana M E Sallum², Cláudia Goldenstein-Schainberg³, Eloisa Bonfa⁴, Clovis A Silva⁵ and Nadia E Aikawa⁶, ¹Pediatric Rheumatology, University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have…
Abstract Number: 2049 • 2016 ACR/ARHP Annual Meeting
Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
Evelyne Vinet¹, Cristiano S. Moura², Jeffrey R. Curtis³, Christian A. Pineau⁴, Michal Abrahamowicz² and Sasha Bernatsky⁵, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, AL, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during RA pregnancy. Most of these are actively transported across the placenta, reaching higher fetal than maternal…
Abstract Number: 523 • 2016 ACR/ARHP Annual Meeting
Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Jerome Avouac¹, Fazia Amrouche², Christophe Meune³, Grégoire Rey⁴, Andre Kahan⁵ and Yannick Allanore⁶, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Cochin Hospital, Paris, France, ³Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, ⁴Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France, ⁵Service de Rhumatologie A, Hopital Cochin, Paris Cedex 14, France, ⁶Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on the disease activity, severity and associated comorbidities. Our objective was…
Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Yumiko SUGIYAMA^1,2, Maasa Tamura^1,2,3, Ryusuke Yoshimi^1,2, Naoki Hamada^1,2, Hideto Nagai^1,2, Yuko Tatekabe^1,2, Naomi Tsuchida^2,4, Yutaro Soejima^1,2, Yosuke Kunishita^2,4, Daiga Kishimoto^1,2, Hiroto Nakano^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^2,5, Yukiko Asami^1,2, Yohei Kirino^2,4, Shigeru Ohno^2,5 and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Y-CURD Study Group, Yokohama, Japan, ³Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁵Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Cristiane Medeiros¹, Luciana Seguro², Fernando Henrique Carlos de Souza², Nadia E Aikawa³ and Eloisa Bonfa⁴, ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].